Targacept Company Description
Depressed because you can't smoke anymore? Targacept might be able to help as it researches how to put the nervous system's nicotinic receptors to good use. The biotechnology company is the result of nicotine research conducted by R.J. Reynolds Tobacco, which spun off the firm in 2000. Targacept's drug candidates address conditions related to cognitive impairment, depression, and pain by targeting neuronal nicotinic receptors (NNRs) in the nervous system using non-nicotine compounds. The firm hopes its drug candidates will reproduce the therapeutic effects of NNR interaction without the side effects of nicotine (but they may not offer that smooth, satisfying taste).
View the Comprehensive Company Description for Targacept
The Company Description provides a historical perspective of Targacept's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Targacept's evolution in the marketplace.
